Julia J. Wattacheril, MD, MPH

Academic Appointments

  • Associate Professor of Medicine at CUMC

Current Administrative Positions

  • Director of the Nonalcoholic Fatty Liver Disease Program
  • Attending, New York - Presbyterian Hospital

This provider accepts new patients

Appointment Phone Number: (212) 305-0914

Julia J. Wattacheril, MD, MPH

Dr. Wattacheril's clinical specialties include all aspects of transplant hepatology, general hepatology and gastroenterology with emphasis on metabolic liver disease and obesity. She specializes in nonalcoholic fatty liver disease as well as all forms of hepatitis, chronic liver disease, and liver cancer in addition to liver transplantation. Her research interests include hepatic steatosis, insulin resistance, gut hormones and metabolic liver disease in adults. Her current research concentrates on the relationship between proteins and lipids that differentiate steatosis from steatohepatitis using an integrated omics approach.

Board Certifications

  • Gastroenterology
  • Transplant Hepatology
  • Internal Medicine

Areas of Expertise

  • Chronic Liver Disease
  • Hereditary Liver Disease
  • Liver Disease
  • Liver Transplantation
  • Non-Alcoholic Fatty Liver Disease
  • Non-Alcoholic Steatohepatitis

Languages Spoken

  • Spanish

Education and Training

  • Residency: Baylor Hospital
  • Fellowship: Vanderbilt University Medical Center
  • Fellowship: 2011 NewYork-Presbyterian Hospital/Columbia University Medical Center


  • CUMC/Presbyterian Hospital and Vanderbilt Clinic

    622 West 168th Street
    New York, NY 10032
    For new and current patient appointments, call:
    (212) 305-0914

Provider Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian / Weill Cornell Medical Center

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

  • Aetna [EPO, HMO, Medicare Managed Care, NYP Employee Plan, NY Signature, POS, PPO, Signature Administrators, Student Health]
  • Affinity [Essential Plan, Medicaid Managed Care]
  • AgeWell [Medicare Managed Care, Special Needs Plan]
  • Amida Care [Special Needs Plan]
  • Capital District Physician Health Plan [Capital District Physician Health Plan]
  • Cigna [EPO, Great West, HMO, POS, PPO]
  • Elderplan [Medicare Managed Care]
  • Emblem/GHI [Medicare Managed Care, PPO]
  • Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
  • Empire Blue Cross/Blue Shield [EPO, Medicare Managed Care, PPO]
  • Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
  • Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]
  • Healthfirst [Child/Family Health Plus, Leaf (Exchange), Medicaid Managed Care, Medicare Managed Care]
  • Local 1199 [Local 1199]
  • MagnaCare [MagnaCare]
  • Medicare [Traditional Medicare (NY)]
  • Multiplan [Multiplan]
  • MVP Health Care [Child/Family Health Plus, Essential Plan, HMO, Medicaid Managed Care]
  • Oxford Health Plans [Freedom, Liberty]
  • UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
  • VNSNY CHOICE [Medicare Managed Care, SelectHealth, Special Needs Plan]
  • WellCare [Medicaid Managed Care, Medicare Managed Care]


  • The Tipping Point in NASH: Detecting Hepatic Lipid Differences in their Microenvironment using Matri Imaging Mass Spectrometry (MALDI- IMS); AASLD poster presentation 2011, San Francisco, CA
  • Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancers DDW oral presentation 2008, San Diego, CA
  • Gastroduodenal Melanosis: A Case Report and Review, presented at Baylor College of Medicine Research Symposium, 2006, Houston, TX

Committees / Societies / Memberships

  • New York Genome Center, affiliate member
  • American Liver Foundation, NY chapter, Medical Advisory Committee member
  • Institute forGenomic Medicine, member
  • New York Academy of Sciences, member
  • Texas Medical Association, member
  • American Association for the Study of Liver Diseases, member
  • American Liver Foundation, Medical Advisory Committee,member
  • American Board of Internal Medicine, member
  • American Gastroenterological Association, member
  • American Society of Human Genetics, member
  • European Society of Human Genetics, member
  • National Valedictorian Society, member

Honors and Awards

  • 2018 Liver Forum, academic investigator
  • 2018 Noninvasive Biomarkers of Metabolic Liver Disease (NIMBLE) consortium, academic investigator
  • 2003 Alpha Omega Alpha
  • 2000 Glasgow-Rubin Achievement Citation recipient, American Medical Women’s Association



  1. *Pomenti S, Gandle C, Abu Sbeih H, Phipps M, Livanos A, Guo A, Yeh J, Burney H, Liu H, Dakhoul L, Kettler C, Gawrieh S, deLemos A, Scanga A, Chalasani N, Miller E, Wattacheril J. Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort. Hep Communications2020: doi.org/10.1002/hep4.1575
  2. *Phipps M, Livanos A, Guo A, Pomenti S, Yeh J, Dakhoul L, Burney H, Kettler C, Liu H, Miller E, GawriehS, deLemos A, Scanga A, Chalasani N, Wattacheril J. Gender Matters: Characteristics of Hepatocellular Carcinoma in Women from a Large, Multicenter Study in the United States. Am J Gastroenterol2020: doi: 10.14309/ajg.0000000000000643.
  3. deLemos, A, Patel M, Gawrieh S, Burney H, Dakhoul L, Miller E, Scanga A, Kettler C, Liu H, Roche P, Wattacheril J, Chalasani N. Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients with Alcohol-Related Liver Disease: A US Multicenter Study. Clin Transl Gastroenterol2020: doi: 10.14309/ctg.0000000000000139.
  4. Siddiqui MS, Van Natta ML, Connelly MA, Vuppalanchi R, Neuschwander-Tetri BA, Tonascia J, Guy C, Loomba R, Dasarathy S, Wattacheril J,Chalasani N, Sanyal AJ; NASH-CRN. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. J Hepatology2020 doi: 10/1016/j.hep.2019.10.006
  5. *Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, Kettler C, Burney H, Liu H, Abu-Sbeih H, Chalasani N, Wattacheril J.Characteristics, Aetiologies and Trends of Hepatocellular Carcinoma in Patients without Cirrhosis: A United States Multicenter Study. Alimentary Pharmacology and Therapeutics.2019 doi.org/10.1111/apt15464
  6. Wattacheril J, Shea PR, Mohammad S, Behlin C, Aggarwal V, Wilson LA, Yates KP, Ito J, Fishbein M, Stong N, Lavine JE, Goldstein DB. Exome sequencing of an adolescent with nonalcoholic fatty liver disease identifies a clinically actionable case of Wilson Disease. Cold Spring Harb Mol Case Stud.2018 Oct 1.doi: 0.1101/mcs.a003087
  7. Wattacheril J, Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston JP, Loomba R, Brunt EM, Chen YI, Goodarzi MO, Taylor KD, Yates KP, Tonascia J, Rotter JI. Genome Wide Associations Related to Hepatic Histology in Nonalcoholic Fatty Liver Disease in Hispanic Boys. J Pediatr. 2017 Nov. doi:10.1016/j.jpeds.2017.08.004
  8. WattacherilJ,Rose,K.L.,Hill,S.,Lanciault,C.,Murray,C.R.,Washington,K.,Williams,B.,English,W.,Spann,M.,Clements,R.,Abumrad,N., andFlynn,C.R.(2017)NAFLDPhosphoproteomics:AFunctionalPieceofthePrecisionPuzzle.HepatolRes, doi:10.1111/hepr.12885.
  9. CoreyKE,GawriehS,deLemosAS,ZhengH,ScangaAE,HaglundJW,SanchezJ,DanfordCJ,ComerfordM,BossiK,MunirS,ChalasaniN,WattacherilJ.Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study. World J Hepatol2017; 9(7): 385-390
  10. Guo Y, Xiong Y, Sheng Q, Zhao S,Wattacheril J, Flynn CR. A micro-RNA expression signature for human NAFLD progression. J Gastroenterol. 2016 Feb 13.
  11. Garcia A, Kasim N, Gonzalez, R, Antoun J, Eckert E, Marks P, Wattacheril J, Abumrad N, Tamboli R, Walle T, Dunn J, Flynn CR. Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease. PLoS One.2015 Nov 23;10(11):e0142676. doi: 10.1371/journal.pone.0142676
  12. Sharifnia T, Antoun J, Suarez G, Wattacheril J, Wilson K, Peek RM, Abumrad N, and Flynn CF. Hepatic TLR4 Signaling in Obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015 Aug 15;309(4):G270-8. doi: 10.1152/ajpgi.00304.2014

For a complete list of publications, please visit PubMed.gov